Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Members of the metallothionein (MT) family are involved in metal detoxifcation and in the protection of cells against certain electrophilic carcinogens. In present study, it was found that MT1M was downregulated in more than 77.1% (91/118) of hepatocellular carcinoma (HCC) tissues compared with adja...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-05, Vol.8 (20), p.33037-33046
Main Authors: Fu, Cheng-Lin, Pan, Bing, Pan, Ju-Hua, Gan, Mei-Fu
Format: Article
Language:English
Subjects:
Aged
Animals
Biomarkers, Tumor - metabolism
Carcinoma, Hepatocellular - metabolism
Cell Line, Tumor
Cell Movement
Cell Proliferation
Cell Survival
Down-Regulation
Female
Gene Expression Regulation, Neoplastic
Hep G2 Cells
Humans
Liver Neoplasms - metabolism
Male
Metallothionein - metabolism
Mice
Mice, Nude
Middle Aged
Neoplasm Transplantation
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Members of the metallothionein (MT) family are involved in metal detoxifcation and in the protection of cells against certain electrophilic carcinogens. In present study, it was found that MT1M was downregulated in more than 77.1% (91/118) of hepatocellular carcinoma (HCC) tissues compared with adjacent non-tumor tissues. Furthermore, overexpression of MT1M inhibited cell viability, colony formation, cell migration and invasion in HCC cell lines and tumor cell growth in xenograft nude mice, and activated cell apoptosis in HCC cell lines. In addition, immunohistochemistry analysis showed MT1M was negative or weak staining in tumor tissues but moderate or strong staining in adjacent non-tumor tissues. The sensitivity and specificity of MT1M for HCC diagnosis were 76.27% and 89.83%, respectively. In conclusion, MT1M was identified as a potential tumor marker for HCC and may serve as a useful therapeutic agent for HCC gene therapy.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.16521